Changes in bile acid subtypes and improvements in lipid metabolism and atherosclerotic cardiovascular disease risk: the Preventing Overweight Using Novel Dietary Strategies (POUNDS Lost) trial.
Study Goal
The researchers aimed to determine whether changes in circulating bile acid subtypes induced by weight-loss dietary interventions were associated with improved lipid profiles and atherosclerotic cardiovascular disease (ASCVD) risk estimates.
Results Summary
The study found that decreases in specific bile acid subtypes were linked to improved lipid profiles and reduced ASCVD risk estimates, suggesting that dietary interventions affecting bile acid metabolism may benefit lipid homeostasis and cardiovascular health.
Population
Adults with overweight or obesity (n = 536).
Effective Dosage
Not specified.
Duration
6 months.
Interactions
None mentioned.
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
weight-loss dietary interventions | decrease | primary BAs | adults with overweight or obesity | - | induced decreases | #1 |
weight-loss diet-induced decreases in primary BAs | decrease | triglycerides | adults with overweight or obesity | - | were related to larger reductions | #2 |
weight-loss diet-induced decreases in primary BAs | decrease | total cholesterol | adults with overweight or obesity | - | were related to larger reductions | #3 |
every 1 standard deviation (SD) decrease of glycocholate | decrease | total cholesterol | adults with overweight or obesity | -3.3 (1.3) mg/dL | was related to | #4 |
every 1 standard deviation (SD) decrease of glycochenodeoxycholate | decrease | total cholesterol | adults with overweight or obesity | -3.4 (1.3) mg/dL | was related to | #5 |
every 1 standard deviation (SD) decrease of taurochenodeoxycholate | decrease | total cholesterol | adults with overweight or obesity | -3.8 (1.3) mg/dL | was related to | #6 |
decreases in distinct BA subtypes | improvement | lipid profiles | adults with overweight or obesity | - | were associated with improved | #7 |
decreases in distinct BA subtypes | improvement | ASCVD risk estimates | adults with overweight or obesity | - | were associated with improved | #8 |
habitual dietary fat intake | neutral | ASCVD risk | adults with overweight or obesity | - | may modify the associations of changes in BAs with | #9 |
BACKGROUND: Distinct circulating bile acid (BA) subtypes may play roles in regulating lipid homeostasis and atherosclerosis. OBJECTIVES: We investigated whether changes in circulating BA subtypes induced by weight-loss dietary interventions were associated with improved lipid profiles and atherosclerotic cardiovascular disease (ASCVD) risk estimates. METHODS: This study included adults with overweight or obesity (n = 536) who participated in a randomized weight-loss dietary intervention trial. Circulating primary and secondary unconjugated BAs and their taurine-/glycine-conjugates were measured at baseline and 6 mo after the weight-loss diet intervention. The ASCVD risk estimates were calculated using the validated equations. RESULTS: At baseline, higher concentrations of specific BA subtypes were related to higher concentrations of atherogenic very low-density lipoprotein lipid subtypes and ASCVD risk estimates. Weight-loss diet-induced decreases in primary BAs were related to larger reductions in triglycerides and total cholesterol [every 1 standard deviation (SD) decrease of glycocholate, glycochenodeoxycholate, or taurochenodeoxycholate was related to β (standard error) -3.3 (1.3), -3.4 (1.3), or -3.8 (1.3) mg/dL, respectively; P CONCLUSIONS: Decreases in distinct BA subtypes were associated with improved lipid profiles and ASCVD risk estimates, highlighting the importance of changes in circulating BA subtypes as significant factors linked to improved lipid metabolism and ASCVD risk estimates in response to weight-loss dietary interventions. Habitual dietary fat intake may modify the associations of changes in BAs with ASCVD risk. This trial was registered at clinicaltrials.gov as NCT00072995.